Do analysts prefer STIM or PETV?

Neuronetics presently has a consensus price target of $3.00, indicating a potential upside of 147.93%. Given Neuronetics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Neuronetics is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuronetics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is STIM or PETV more profitable?

Neuronetics has a net margin of -24.48% compared to PetVivo's net margin of -902.82%. Neuronetics' return on equity of -139.83% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -24.48% -139.83% -27.13% PetVivo -902.82% -4,813.07% -281.78%

Do analysts prefer PETV or LAKE?

Lakeland Industries has a consensus target price of $16.00, indicating a potential upside of 58.73%. Given Lakeland Industries' stronger consensus rating and higher possible upside, analysts plainly believe Lakeland Industries is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lakeland Industries 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is PETV or LAKE more profitable?

Lakeland Industries has a net margin of -10.87% compared to PetVivo's net margin of -902.82%. Lakeland Industries' return on equity of -6.64% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets PetVivo -902.82% -4,813.07% -281.78% Lakeland Industries -10.87% -6.64% -4.13%

Does the media prefer PETV or LAKE?

In the previous week, Lakeland Industries had 4 more articles in the media than PetVivo. MarketBeat recorded 7 mentions for Lakeland Industries and 3 mentions for PetVivo. Lakeland Industries' average media sentiment score of 0.25 beat PetVivo's score of 0.00 indicating that Lakeland Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lakeland Industries 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PETV or INO?

Inovio Pharmaceuticals has a consensus price target of $4.25, indicating a potential upside of 282.88%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Inovio Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Does the media refer more to PETV or INO?

In the previous week, PetVivo had 2 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 3 mentions for PetVivo and 1 mentions for Inovio Pharmaceuticals. PetVivo's average media sentiment score of 0.00 equaled Inovio Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inovio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PYPD or PETV?

PolyPid presently has a consensus target price of $11.67, suggesting a potential upside of 155.85%. Given PolyPid's stronger consensus rating and higher possible upside, analysts clearly believe PolyPid is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PolyPid 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, PYPD or PETV?

PetVivo has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than PetVivo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.91 N/A PetVivo $1.05M 27.82 -$10.95M -$0.38 N/A

Is PYPD or PETV more profitable?

PolyPid has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. PolyPid's return on equity of -241.96% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -241.96% -126.91% PetVivo -902.82% -4,813.07% -281.78%

Does the media favor PYPD or PETV?

In the previous week, PetVivo had 2 more articles in the media than PolyPid. MarketBeat recorded 3 mentions for PetVivo and 1 mentions for PolyPid. PolyPid's average media sentiment score of 0.53 beat PetVivo's score of 0.00 indicating that PolyPid is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PETV or OM?

Outset Medical has a consensus price target of $10.00, indicating a potential upside of 148.76%. Given Outset Medical's stronger consensus rating and higher possible upside, analysts clearly believe Outset Medical is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Outset Medical 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is PETV or OM more profitable?

Outset Medical has a net margin of -63.65% compared to PetVivo's net margin of -902.82%. Outset Medical's return on equity of -56.13% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets PetVivo -902.82% -4,813.07% -281.78% Outset Medical -63.65% -56.13% -27.45%

Does the media prefer PETV or OM?

In the previous week, PetVivo had 1 more articles in the media than Outset Medical. MarketBeat recorded 3 mentions for PetVivo and 2 mentions for Outset Medical. Outset Medical's average media sentiment score of 0.62 beat PetVivo's score of 0.00 indicating that Outset Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Outset Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PetVivo (PETV) Competitors

$0.80 -0.05 (-6.00%)

As of 11:23 AM Eastern

Compare

PETV vs. STIM, LAKE, INO, PYPD, and OM

Should you buy PetVivo stock or one of its competitors? MarketBeat compares PetVivo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PetVivo include Neuronetics (STIM), Lakeland Industries (LAKE), Inovio Pharmaceuticals (INO), PolyPid (PYPD), and Outset Medical (OM). These companies are all part of the "medical equipment" industry.

How does PetVivo compare to Neuronetics?

Neuronetics (NASDAQ:STIM) and PetVivo (NASDAQ:PETV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

PetVivo has lower revenue, but higher earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than PetVivo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	0.56	-$39M	-$0.54	N/A
PetVivo	$1.05M	27.82	-$10.95M	-$0.38	N/A

Neuronetics presently has a consensus price target of $3.00, indicating a potential upside of 147.93%. Given Neuronetics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Neuronetics is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Neuronetics has a net margin of -24.48% compared to PetVivo's net margin of -902.82%. Neuronetics' return on equity of -139.83% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-24.48%	-139.83%	-27.13%
PetVivo	-902.82%	-4,813.07%	-281.78%

Neuronetics has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, PetVivo has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 24.5% of PetVivo shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by company insiders. Comparatively, 10.8% of PetVivo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, PetVivo had 3 more articles in the media than Neuronetics. MarketBeat recorded 3 mentions for PetVivo and 0 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.89 beat PetVivo's score of 0.00 indicating that Neuronetics is being referred to more favorably in the media.

Company	Overall Sentiment
Neuronetics	Very Positive
PetVivo	Neutral

Summary

Neuronetics beats PetVivo on 9 of the 16 factors compared between the two stocks.

How does PetVivo compare to Lakeland Industries?

PetVivo (NASDAQ:PETV) and Lakeland Industries (NASDAQ:LAKE) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

24.5% of PetVivo shares are owned by institutional investors. Comparatively, 71.7% of Lakeland Industries shares are owned by institutional investors. 10.8% of PetVivo shares are owned by company insiders. Comparatively, 3.4% of Lakeland Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lakeland Industries has a net margin of -10.87% compared to PetVivo's net margin of -902.82%. Lakeland Industries' return on equity of -6.64% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
Lakeland Industries	-10.87%	-6.64%	-4.13%

PetVivo has higher earnings, but lower revenue than Lakeland Industries. Lakeland Industries is trading at a lower price-to-earnings ratio than PetVivo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	27.82	-$10.95M	-$0.38	N/A
Lakeland Industries	$192.65M	0.52	-$25.31M	-$2.13	N/A

In the previous week, Lakeland Industries had 4 more articles in the media than PetVivo. MarketBeat recorded 7 mentions for Lakeland Industries and 3 mentions for PetVivo. Lakeland Industries' average media sentiment score of 0.25 beat PetVivo's score of 0.00 indicating that Lakeland Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakeland Industries	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lakeland Industries has a consensus target price of $16.00, indicating a potential upside of 58.73%. Given Lakeland Industries' stronger consensus rating and higher possible upside, analysts plainly believe Lakeland Industries is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lakeland Industries	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

PetVivo has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, Lakeland Industries has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

Summary

Lakeland Industries beats PetVivo on 11 of the 16 factors compared between the two stocks.

How does PetVivo compare to Inovio Pharmaceuticals?

PetVivo (NASDAQ:PETV) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

24.5% of PetVivo shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 10.8% of PetVivo shares are held by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Inovio Pharmaceuticals has a consensus price target of $4.25, indicating a potential upside of 282.88%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

PetVivo has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Inovio Pharmaceuticals has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. Inovio Pharmaceuticals' return on equity of -489.79% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

In the previous week, PetVivo had 2 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 3 mentions for PetVivo and 1 mentions for Inovio Pharmaceuticals. PetVivo's average media sentiment score of 0.00 equaled Inovio Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inovio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PetVivo has higher revenue and earnings than Inovio Pharmaceuticals. PetVivo is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	27.82	-$10.95M	-$0.38	N/A
Inovio Pharmaceuticals	$60K	1,522.00	-$84.95M	-$1.45	N/A

Summary

Inovio Pharmaceuticals beats PetVivo on 10 of the 15 factors compared between the two stocks.

How does PetVivo compare to PolyPid?

PolyPid (NASDAQ:PYPD) and PetVivo (NASDAQ:PETV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

PolyPid has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, PetVivo has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

In the previous week, PetVivo had 2 more articles in the media than PolyPid. MarketBeat recorded 3 mentions for PetVivo and 1 mentions for PolyPid. PolyPid's average media sentiment score of 0.53 beat PetVivo's score of 0.00 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.5% of PolyPid shares are held by institutional investors. Comparatively, 24.5% of PetVivo shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 10.8% of PetVivo shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

PolyPid presently has a consensus target price of $11.67, suggesting a potential upside of 155.85%. Given PolyPid's stronger consensus rating and higher possible upside, analysts clearly believe PolyPid is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PetVivo has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than PetVivo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
PetVivo	$1.05M	27.82	-$10.95M	-$0.38	N/A

PolyPid has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. PolyPid's return on equity of -241.96% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
PetVivo	-902.82%	-4,813.07%	-281.78%

Summary

PolyPid beats PetVivo on 10 of the 15 factors compared between the two stocks.

How does PetVivo compare to Outset Medical?

PetVivo (NASDAQ:PETV) and Outset Medical (NASDAQ:OM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Outset Medical has a net margin of -63.65% compared to PetVivo's net margin of -902.82%. Outset Medical's return on equity of -56.13% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
Outset Medical	-63.65%	-56.13%	-27.45%

24.5% of PetVivo shares are owned by institutional investors. 10.8% of PetVivo shares are owned by company insiders. Comparatively, 2.5% of Outset Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

PetVivo has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Outset Medical has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market.

PetVivo has higher earnings, but lower revenue than Outset Medical. PetVivo is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	27.82	-$10.95M	-$0.38	N/A
Outset Medical	$119.48M	0.62	-$81.65M	-$4.16	N/A

In the previous week, PetVivo had 1 more articles in the media than Outset Medical. MarketBeat recorded 3 mentions for PetVivo and 2 mentions for Outset Medical. Outset Medical's average media sentiment score of 0.62 beat PetVivo's score of 0.00 indicating that Outset Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Outset Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Outset Medical has a consensus price target of $10.00, indicating a potential upside of 148.76%. Given Outset Medical's stronger consensus rating and higher possible upside, analysts clearly believe Outset Medical is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Outset Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Outset Medical beats PetVivo on 10 of the 16 factors compared between the two stocks.

Get PetVivo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PETV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PETV vs. The Competition

Export

Metric	PetVivo	Surgical & medical instruments Industry	Medical Sector	NASDAQ Exchange
Market Cap	$29.10M	$40.69M	$6.52B	$12.23B
Dividend Yield	N/A	1.08%	2.67%	5.71%
P/E Ratio	-1.78	17.12	24.80	24.08
Price / Sales	27.82	27.62	524.00	110.27
Price / Cash	N/A	18.86	43.94	55.48
Price / Book	-26.63	13.11	10.63	6.61
Net Income	-$10.95M	-$20.39M	$3.57B	$337.89M
7 Day Performance	-0.09%	0.17%	1.42%	1.65%
1 Month Performance	-0.13%	-5.96%	2.01%	3.10%
1 Year Performance	14.14%	-10.24%	27.77%	29.69%

PetVivo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PETV PetVivo	N/A	$0.80 -6.0%	N/A	+21.4%	$29.10M	$1.05M	N/A	20	News Coverage Gap Up
STIM Neuronetics	3.4966 of 5 stars	$1.29 -11.6%	$3.00 +132.6%	-67.1%	$101.60M	$149.16M	N/A	180	Positive News
LAKE Lakeland Industries	3.1104 of 5 stars	$9.28 -6.6%	$15.20 +63.8%	-27.8%	$98.04M	$192.65M	N/A	2,600	Analyst Upgrade
INO Inovio Pharmaceuticals	1.9943 of 5 stars	$1.07 -7.8%	$4.25 +297.2%	-44.5%	$95.44M	$60K	N/A	320	Analyst Upgrade
PYPD PolyPid	2.598 of 5 stars	$4.50 -6.8%	$12.25 +172.2%	+27.0%	$92.17M	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PETV) was last updated on 6/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PetVivo (PETV) Competitors

PETV vs. STIM, LAKE, INO, PYPD, and OM

How does PetVivo compare to Neuronetics?

Summary

How does PetVivo compare to Lakeland Industries?

Summary

How does PetVivo compare to Inovio Pharmaceuticals?

Summary

How does PetVivo compare to PolyPid?

Summary

How does PetVivo compare to Outset Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PETV vs. The Competition

PetVivo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PetVivo (PETV) Competitors

PETV vs. STIM, LAKE, INO, PYPD, and OM

How does PetVivo compare to Neuronetics?

Which has stronger valuation and earnings, STIM or PETV?

Do analysts prefer STIM or PETV?

Is STIM or PETV more profitable?

Which has more volatility & risk, STIM or PETV?

Do insiders and institutionals believe in STIM or PETV?

Does the media favor STIM or PETV?

Summary

How does PetVivo compare to Lakeland Industries?

Do institutionals & insiders have more ownership in PETV or LAKE?

Is PETV or LAKE more profitable?

Which has higher valuation & earnings, PETV or LAKE?

Does the media prefer PETV or LAKE?

Do analysts prefer PETV or LAKE?

Which has more risk and volatility, PETV or LAKE?

Summary

How does PetVivo compare to Inovio Pharmaceuticals?

Do institutionals and insiders have more ownership in PETV or INO?

Do analysts recommend PETV or INO?

Which has more risk and volatility, PETV or INO?

Is PETV or INO more profitable?

Does the media refer more to PETV or INO?

Which has preferable earnings & valuation, PETV or INO?

Summary

How does PetVivo compare to PolyPid?

Which has more volatility & risk, PYPD or PETV?

Does the media favor PYPD or PETV?

Do insiders and institutionals hold more shares of PYPD or PETV?

Do analysts rate PYPD or PETV?

Which has higher earnings & valuation, PYPD or PETV?

Is PYPD or PETV more profitable?

Summary

How does PetVivo compare to Outset Medical?

Is PETV or OM more profitable?

Do institutionals & insiders have more ownership in PETV or OM?

Which has more volatility and risk, PETV or OM?

Which has higher valuation & earnings, PETV or OM?

Does the media prefer PETV or OM?

Do analysts rate PETV or OM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PETV vs. The Competition

PetVivo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools